Micofull

Micofull may be available in the countries listed below.

Ingredient matches for Micofull

Fluconazole

Fluconazole is reported as an ingredient of Micofull in the following countries:

• Dominican Republic

International Drug Name Search

Vérapamil Biogaran

Vérapamil Biogaran may be available in the countries listed below.

Ingredient matches for Vérapamil Biogaran

Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Vérapamil Biogaran in the following countries:

• France

International Drug Name Search

Dramine

Dramine may be available in the countries listed below.

Ingredient matches for Dramine

Meclozine

Meclozine dihydrochloride (a derivative of Meclozine) is reported as an ingredient of Dramine in the following countries:

• Spain

International Drug Name Search

Concerta

Concerta is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

CONCERTA (methylphenidate hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 1, 2000
  
  Strength(s): 18MG, 36MG
  


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: December 8, 2000
  
  Strength(s): 54MG ^[RLD]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: April 1, 2002
  
  Strength(s): 27MG
  

Has a generic version of Concerta been approved?

No. There is currently no therapeutically equivalent version of Concerta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Concerta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods and devices for providing prolonged drug therapy
  Patent 6,919,373
  Issued: July 19, 2005
  Inventor(s): Lam; Andrew C. & Shivanand; Padmaja & Ayer; Atul D. & Weyers; Richard G. & Gupta; Suneel K. & Guinta; Diane R. & Christopher; Carol A. & Saks; Samuel R. & Hamel; Lawrence G. & Wright; Jeri D. & Hatamkhany; Zahedeh
  Assignee(s): Alza Corporation
  Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
  
  Patent expiration dates:
  
  
  • July 31, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING ADHD
  
  
  
  • January 31, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods and devices for providing prolonged drug therapy
  Patent 6,930,129
  Issued: August 16, 2005
  Inventor(s): Lam; Andrew C. & Shivanand; Padmaja & Ayer; Atul D. & Hatamkhany; Zahedeh & Gupta; Suneel K. & Guinta; Diane R. & Christopher; Carol A. & Saks; Samuel R. & Hamel; Lawrence G. & Wright; Jeri D. & Weyers; Richard G.
  Assignee(s): Alza Corporation
  Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
  
  Patent expiration dates:
  
  
  • July 31, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING ADHD
  
  
  
  • January 31, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 27, 2011 - NEW PATIENT POPULATION
  
  
  • November 4, 2012 - ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
  
  

See also...

• Concerta Consumer Information (Drugs.com)
• Concerta Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Concerta Consumer Information (Cerner Multum)
• Concerta Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)

Amrubicin

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0110267-81-7

Chemical Formula

C25-H25-N-O9

Molecular Weight

483

Therapeutic Category

Antineoplastic agent

Chemical Names

(+)-(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione (USAN)

(+)-(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione (WHO)

(+)-9-Amino-4-demethoxy-9-deoxy-7-O-(2-deoxy-β-D-erythro-pentopyranosyl)-daunomycinone

5,12-Naphthacenedione, 9-Acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)- (USAN)

Foreign Names

• Amrubicinum (Latin)
• Amrubicin (German)
• Amrubicine (French)
• Amrubicina (Spanish)

Generic Names

• Amrubicin (OS: USAN)
• UNII-93N13LB4Z2 (IS)
• Amrubicin Hydrochloride (OS: USAN)
• SM-5887 (IS)

Brand Name

• Calsed
  Dainippon Sumitomo, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Deroctyl

Deroctyl may be available in the countries listed below.

Ingredient matches for Deroctyl

Glibenclamide

Glibenclamide is reported as an ingredient of Deroctyl in the following countries:

• Greece

International Drug Name Search

Doctamine

Doctamine may be available in the countries listed below.

Ingredient matches for Doctamine

Butamirate

Butamirate citrate (a derivative of Butamirate) is reported as an ingredient of Doctamine in the following countries:

• Greece

International Drug Name Search

Peripheral Neuropathy Medications

Definition of Peripheral Neuropathy: Peripheral neuropathy is failure of the nerves that carry information to and from the brain and spinal cord. This produces symptoms like pain, loss of sensation, and inability to control muscles.

Drugs associated with Peripheral Neuropathy

The following drugs and medications are in some way related to, or used in the treatment of Peripheral Neuropathy. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Peripheral Neuropathy

• Brachial Plexopathy (0 drugs)

Learn more about Peripheral Neuropathy

Micromedex Care Notes:

• Bell's Palsy
• Carpal Tunnel Syndrome
• Cervical Radiculopathy
• Cervical Spine Strain
• Cubital Tunnel Syndrome
• Diabetic Foot Ulcers
• Diabetic Neuropathy
• Lumbar Radiculopathy
• Meralgia Paresthetica
• Sciatica
• Thoracic Outlet Syndrome
• Trigeminal Neuralgia

Medical Encyclopedia:

• Alcoholic neuropathy
• Amaurosis fugax
• Anesthesia
• Bell's palsy
• Brachial plexopathy
• Brachial plexus injury in newborns
• Carpal tunnel syndrome
• Collagen vascular disease
• Complex regional pain syndrome
• Diabetic neuropathy
• Face pain
• Facial nerve palsy due to birth trauma
• Femoral nerve dysfunction
• Glossopharyngeal neuralgia
• Mononeuritis multiplex
• Mononeuropathy
• Muscle atrophy
• Neuralgia
• Neuropathy secondary to drugs
• Peripheral neuropathy
• Radial nerve dysfunction
• Sciatica
• Trigeminal neuralgia
• Ulnar nerve dysfunction

Drug List:

Carbatrol-Sustained-Release-Capsules

Carnitor

Carnitor-Sf-Solution

Cymbalta

Dilantin

Epitol

Fanatrex

Gabarone

Carnitine

Neurontin

Phenytek-Extended-Release-Capsules

Phenytoin-Sodium-Prompt

Qutenza

Tegretol

Tegretol-Xr-Sustained-Release-Tablets

Cigram

Cigram may be available in the countries listed below.

Ingredient matches for Cigram

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Cigram in the following countries:

• Colombia

International Drug Name Search

Diclo KSK

Diclo KSK may be available in the countries listed below.

Ingredient matches for Diclo KSK

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclo KSK in the following countries:

• Germany

International Drug Name Search

Gentran 70

In the US, Gentran 70 (dextran, high molecular weight systemic) is a member of the drug class plasma expanders.

US matches:

• Gentran 70

Ingredient matches for Gentran 70

Dextran

Dextran average molecular weight about 70000 (a derivative of Dextran) is reported as an ingredient of Gentran 70 in the following countries:

• Luxembourg


• United States

International Drug Name Search

Reopro

Generic Name: abciximab (Intravenous route)

ab-SIX-i-mab

Commonly used brand name(s)

In the U.S.

• Reopro

Available Dosage Forms:

• Solution

Therapeutic Class: Platelet Aggregation Inhibitor

Pharmacologic Class: Glycoprotein IIb/IIIa Inhibitor

Uses For Reopro

Abciximab is used to lessen the chance of heart attack in people who need percutaneous coronary intervention (PCI), a procedure to open blocked arteries of the heart.

A heart attack may occur when a blood vessel in the heart is blocked by a blood clot. Blood clots can sometimes form during PCI. Abciximab reduces the chance that a harmful clot will form by preventing certain cells in the blood from clumping together. Abciximab is used with aspirin and heparin, which are other medicines used to keep your blood from clotting.

This medicine is available only with your doctor's prescription.

Before Using Reopro

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of abciximab in children with use in other age groups.

Geriatric

Bleeding problems may be especially likely to occur in elderly patients, who are usually more sensitive than younger adults tot the effects of abciximab. It is important that you discuss the use of this medicine with your doctor.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Acenocoumarol


• Alteplase, Recombinant


• Argatroban


• Bivalirudin


• Bromfenac


• Celecoxib


• Cilostazol


• Citalopram


• Dabigatran Etexilate


• Dalteparin


• Danaparoid


• Desirudin


• Desvenlafaxine


• Dextran


• Diclofenac


• Diflunisal


• Drotrecogin Alfa


• Duloxetine


• Enoxaparin


• Escitalopram


• Etodolac


• Fluoxetine


• Flurbiprofen


• Fluvoxamine


• Fondaparinux


• Heparin


• Ibuprofen


• Ibuprofen Lysine


• Indomethacin


• Ketoprofen


• Ketorolac


• Lepirudin


• Magnesium Salicylate


• Mefenamic Acid


• Meloxicam


• Milnacipran


• Nabumetone


• Naproxen


• Nefazodone


• Nepafenac


• Oxaprozin


• Paroxetine


• Phenindione


• Phenprocoumon


• Piroxicam


• Protein C, Human


• Rivaroxaban


• Salsalate


• Sertraline


• Sulindac


• Ticlopidine


• Tinzaparin


• Tolmetin


• Warfarin

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Vitamin A

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Aneurysm (swelling in a blood vessel) especially in the head or


• Blood disease or a history of unusual bleeding or


• Brain problems which may include bleeding, disease, injury or tumor or


• If you weigh less than 150 pounds or


• If you are over 65 years of age or


• Injury to any part of the body or


• Liver disease or


• Stroke—The risk of bleeding may be increased

Also, tell your doctor if you have received abciximab or heparin before and had a reaction to either of them called thrombocytopenia (a low platelet count in the blood), or if new blood clots formed while you were receiving the medicine.

In addition, tell your doctor if you have recently had any bleeding from the stomach, previously had a stroke, recently fallen or suffered a blow to the body or head, or had major medical or dental surgery . These events may increase the risk of serious bleeding when you are taking abciximab.

Proper Use of Reopro

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For injection dosage form:
  
  • For prevention of blood clots during percutaneous coronary intervention (the procedure to open blocked blood vessels):
    
    • Adults—Initial dose: 250 micrograms (mcg) per kilogram (kg) of body weight injected 10 to 60 minutes before the procedure. Maintenance dose: 0.125 mcg per kg of body weight per minute (maximum of 10 mcg per minute) by IV for 12 hours.
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  
  • For patients with unstable angina that will undergo percutaneous coronary intervention within 24 hours:
    
    • Adults—Initial dose: 250 micrograms (mcg) per kilogram (kg) of body weight injected. Maintenance dose: 10 mcg per minute by IV for 18 to 24 hours, ending 1 hour after the procedure.
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  

Precautions While Using Reopro

Tell all of your medical doctors and dentists that you are using this medicine.

Check with your doctor immediately if you notice any of the following side effects:

• Bruising or bleeding, especially bleeding that is hard to stop. Bleeding inside the body sometimes appears as bloody or black, tarry stools, or faintness.


• Back pain; burning, pricking, tickling, or tingling sensation; leg weakness; numbness; paralysis; or problems with bowel or bladder function.

Reopro Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

More common

• Bleeding


• blurred vision; confusion; dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly; sweating; unusual tiredness or weakness

Less common

• Black, tarry stools


• bleeding gums


• blood in urine or stools


• pinpoint red spots on skin


• unusual bleeding or bruising

Rare

• Chest pain or discomfort


• chills


• cough


• eye pain


• fever


• general feeling of illness


• headache


• pale skin


• rapid weight gain


• shortness of breath


• slow or irregular heartbeat


• sneezing


• sore throat


• swelling of hands, ankles, feet, or lower legs


• tightness in chest


• tingling of hands or feet


• troubled breathing


• unusual tiredness


• wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

• Back pain

Less common

• Acid or sour stomach


• belching


• burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings


• changes in vision


• delusions


• dementia


• fear


• heartburn


• indigestion or stomach discomfort, upset or pain


• mood or mental changes


• nausea


• nervousness


• vomiting

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Reopro side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Reopro resources

• Reopro Side Effects (in more detail)
• Reopro Use in Pregnancy & Breastfeeding
• Reopro Drug Interactions
• Reopro Support Group
• 0 Reviews for Reopro - Add your own review/rating

• Abciximab Professional Patient Advice (Wolters Kluwer)


• ReoPro Prescribing Information (FDA)


• ReoPro Monograph (AHFS DI)


• ReoPro MedFacts Consumer Leaflet (Wolters Kluwer)


• ReoPro Consumer Overview

Compare Reopro with other medications

• High Risk Percutaneous Transluminal Angioplasty

Bonemax

Bonemax may be available in the countries listed below.

Ingredient matches for Bonemax

Alendronic Acid

Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Bonemax in the following countries:

• Turkey

International Drug Name Search

Rinderon-DP

Rinderon-DP may be available in the countries listed below.

Ingredient matches for Rinderon-DP

Betamethasone

Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Rinderon-DP in the following countries:

• Japan

International Drug Name Search